טוען...
Prognostic Models to Predict Survival in Non-Small Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab
PURPOSE: Determine prognostic factors and build a model to predict one-year overall survival (1Y-OS) and six-month progression free survival (6M-PFS) in advanced non-small cell lung cancer (NSCLC) patients treated with first-line paclitaxel and carboplatin (PC) with or without bevacizumab. MATERIALS...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3433686/ https://ncbi.nlm.nih.gov/pubmed/22843087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318260e106 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|